Key Takeaways
- Volume at low end, margin squeezed: FY23 volume grew ~10% (bottom of 10–15% guidance) while EBITDA margins narrowed on Acetonitrile and Ethylamine pricing pressure, partly offset by a Q4 gross margin uptick.
- Acetonitrile pricing at multi-year lows: Dollar prices are the lowest in a long time as Chinese supply returns; management hopes the floor is near but won’t call a recovery.
- Ethylamine caught in a cost-price vise: Alcohol input costs rose but finished goods prices did not follow because of competition, compressing margins in a core product line.
- New products are the medium-term story: Diethylketone is commissioned and four more launches are planned; together they could reach ₹500–600 crores turnover and 15–20% of top line over 3–4 years.
- What to watch next quarter: Whether the Ethylamines expansion commissions on schedule in Q2, any sign that Acetonitrile pricing has bottomed, and the pace of Pharma demand recovery that management is betting on.
Volume & Demand Environment
- FY23 volume landed at the guide’s floor: Management had predicted 10–15% volume growth and achieved around 10%, calling it the lower end of the range.
- Pharma destocking was the drag: The Pharma industry overproduced during COVID, then spent the year destocking; industry production and sales were only 2–3% higher while inventories were worked down.
- FY24 volume ambition: Expecting to be a little better, hoping to hit the higher end of 10–15% volume growth.
- Pharma outlook is cautiously better: Management sees Pharma as essential with low drug penetration in India (30–40% of population uses allopathic medicines); after a rough destocking year, it will be better than last year, though some not-so-good quarters will still occur.
- Exports grew share but face macro headwinds: Exports rose to 22–23% of sales from a little under 20%, helped by settling freight and container issues; current challenge is economic growth abroad, mainly Europe and America.
Kirat Patel: "I would say that we hope that we have got over the worst volatile period, and we are looking forward to now growth, especially because our customers mainly in the Pharma industry seem to be so optimistic, and our raw material prices are stabilizing."
Margin Drivers & Cost Structure
- Two products drove the margin contraction: Acetonitrile finished goods prices narrowed, and Ethylamine margins dropped because alcohol input prices rose while finished goods prices stayed flat due to competition. These two are the main reasons margins fell a few basis points versus the past.
- Gross margins actually improved QoQ: Gross margins in Q4 were about a couple of percentage points higher than Q3, so the margin story is not a simple decline.
- Coal was the big other-expense item: Other expenses rose last year largely on account of coal; coal prices went up considerably but now appear to have settled. Management hopes coal prices come down, which would reduce utility costs.
- Solar capacity is being built out: A solar facility was commissioned as part of ₹140 crores of capitalized projects; another solar plant is planned for the Dahej site in Gujarat, which will further reduce electricity costs.
- No pass-through safety net: The company has no pass-through arrangements with customers; pricing is pure market dynamics. Because competitors share similar raw material exposure and technologies, Alkyl Amines must stay in line with the market or lose share.
Kirat Patel: "It's not a one-way street that the prices come down and we can retain our benefits. Okay, it happens in some peculiar circumstances, but it's not a general rule."
Acetonitrile: The Pricing Overhang
- Prices at multi-year dollar lows: Acetonitrile is floating around ₹150/kg, and in dollar terms prices are among the lowest seen for a long time. The driver is increased supply as Chinese producers have settled issues and returned to the global market.
- Management hopes the floor is near: Q4 exit pricing is where it is and shouldn’t get worse; $2/kg is described as pretty low. There is a little overhang of Chinese inventory still cleaning up, and once that is done some kind of normal season may return.
- Acetic acid relief may widen margins: Acetonitrile margins narrowed because finished goods prices fell; acetic acid, a key input, is now coming down, so management hopes margins will widen again.
- Experience is the competitive moat at the bottom: If the company can sustain current margins at these low prices, it will always have an edge over newcomers because its experience in making the product makes it far more efficient.
Kirat Patel: "This has been among the lowest prices we have seen, and if we are able to sustain this margin, we will always have an edge over the newcomer because our experience in making this product makes us far more efficient than the newcomer."
Competitive Dynamics & Imports
- Chinese imports intensified in Q4: The quarter faced a little more competition from imports, mainly Chinese; finished goods prices matter for margins just as much as raw material prices.
- Imports are the permanent benchmark: Most products are replacing imports, and competition is global. If Alkyl Amines doesn’t make a product, people will import it; even if they do make it, people will still import if it’s cheaper.
- Market share is a constant struggle: Even in domestic methylamine, where the company might expect to retain raw material cost benefits, competition exists and market share struggle will remain.
New Products & Capacity Build-Out
- Diethylketone is live and stabilizing: The Diethylketone plant was commissioned in the last year and has stabilized in production; it has been in the market only a couple of months.
- Market share ambition for Diethylketone: Aiming for about 50–60% market share over the next 18 months, with efforts to establish the product and debottleneck capacity over that period.
- Four more launches in the pipeline: About five products were to be launched over 24 months from the last meeting; six months have passed and one (Diethylketone) is done. The remaining are not all from the amine family: one or two are derivatives, others are specialties.
- New products as a top-line and bottom-line lever: Over a 3-to-4-year period, 4–5 new products including Diethylketone may comprise almost 15–20% of top line and hopefully a larger portion of bottom line. Once stabilized, turnover could be between ₹500–600 crores, per an off-the-cuff management estimate.
- Ethylamines expansion imminent: The Ethylamines expansion is almost ready and will probably be commissioned in Q2 of this financial year (July–September).
- Land secured for the next wave: All land in Dahej and Kurkumbh has been allocated to new products and expansion plans over the next 18–24 months; an application for additional land from GIDC in Gujarat is in process, with progress expected by mid-2023, though any down payments are at least 12 months away.
- CapEx trajectory: FY23–24 CapEx is around ₹200 crores; for products required across FY23, FY24 and FY25, the outlay is about ₹300 crores, ₹200 crores and ₹100 crores respectively.
Margin Recovery Path
- Management won’t forecast margins: The company only gives broad volume indications, not margin guidance, because margins have varied quite widely and unexpectedly.
- The recovery thesis rests on raw material stabilization: Management is hopeful that given raw material prices seem to be coming down, they would get some advantage, but they will not speculate on how much.
- Volume bridge to prior profitability: To match FY22 PAT at current margins, the company would need about 20–25% volume growth; if margins widen a bit, only 15% is needed.
- Acetonitrile and Ethylamine are already improving: Both products seem to be doing a little better now; management is looking forward to better times.
Kirat Patel: "We normally do not speculate on our future margins, because it's very difficult. We only give a broad indication of volumes which we expect because margins, as you know, have varied quite widely and unexpectedly, we do well, and unexpectedly we don't do so well."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | Higher end of 10–15% range | FY24 |
| Ethylamines expansion commissioning | Plant almost ready | Q2 FY24 (July–September) |
| Diethylketone market share | 50–60% | Over next 18 months |
| New product launches | 4 remaining products (derivatives and specialties) | Over next ~18 months (24 months from prior meeting, 6 months elapsed) |
| New products turnover | ₹500–600 crores (off-the-cuff estimate) | Once stabilized (3–4 year horizon) |
| New products top-line contribution | 15–20% of top line, larger portion of bottom line | 3–4 year period |
| CapEx | ~₹200 crores | FY23–24 |
| Land allocation progress from GIDC | Some progress expected | By mid-2023 |
| Solar plant for Dahej | Planned, to reduce electricity costs | No date given |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹1,700 cr (full-year FY23, per an analyst's math) |
| Volume growth | ~10% YoY (FY23), at the lower end of 10–15% guidance |
| Gross margin | Improved a couple of percentage points QoQ in Q4 |
| EBITDA margin | Contracted vs historical levels; was up 400–500 bps until Sep '21 (per an analyst's math) |
| PAT (FY22 reference) | Little less than ₹300 cr (FY22); 20–25% volume growth needed at current margins to match |
| Exports share | 22–23% of sales (FY23), up from under 20% |
| Revenue mix | 50% amines, 20–25% derivatives, 20–25% specialties |
| Acetonitrile realization | ₹150 per Kg, among the lowest dollar prices seen for a long time |
| Acetonitrile capacity utilization | 60–65% across old and new plants (total 28,000–30,000 tons per annum) |
| Raw material basket cost | 10–15% drop from peak |
| Ammonia cost weight | 15–20% of raw material costs; 60–70% price drop could save 4–5% vs last year |
| Coal price | ~₹11,000 per ton, down from peak of ₹14,000–₹15,000 per ton |
| Ethylamines expansion spend | ₹400 cr planned; ~80% of ₹352 cr capital work in progress |
| FY24 CapEx guidance | ~₹200 cr (FY24), ₹100 cr (FY25), excluding land |
| New products revenue potential | ₹500–600 cr once stabilized, 15–20% of top line over 3–4 years |